Advanced Formulation Design: Improving Drug Therapies for the Management of Severe and Chronic Pain

REFERENCES

• Adams M. P., Ahdieh H. Pharmacokinetics and dose-proportionality of oxymorphone ER and its metabolites: Results of a randomized crossover study. Pharmacotherapy 2004; 24: 468–476
   PubMed Web of Science ®Google Scholar
• Alpharma Pharmaceuticals. Kadian [Package insert]. Author, Piscataway, NJ 2007
   Google Scholar
• Amabile C. M., Bowman B. J. Overview of oral modified-release opioid products for the management of chronic pain. Ann. Pharmacother. 2006; 40: 1327–1335
   PubMed Web of Science ®Google Scholar
• American Pain Society. Principles of analgesic use in the treatment of acute pain and cancer pain. Author, Glenview, IL 1999; 1–64
   Google Scholar
• Anderson D. T., Fritz K. L., Muto J. J. OxyContin: The concept of a “ghost pill” and the postmortem tissue distribution of oxycodone in 36 cases. J. Anal. Toxicol. 2002; 26: 448–459
   PubMed Web of Science ®Google Scholar
• Baichwal A., Neville D. A. Culturing innovation and enhancing medications using oral drug delivery. Drug Delivery Technology 2002; 2: 65–68
   Google Scholar
• Berner B., Cowles V. Case studies in swelling polymeric gastric retentive tablets. Expert Opinion on Drug Delivery 2006; 3: 541–548
   PubMedGoogle Scholar
• Beyssac E., Touaref F., Meyer M., Jacob L., Sandouk P., Aiache J. M. Bioavailability of morphine after administration of a new bioadhesive buccal tablet. Biopharm. Drug Dispos. 1998; 19: 401–405
   PubMed Web of Science ®Google Scholar
• Boroda C., Miller R. B., Leslie S. T., Nicol E. G., Thomson I. Comparision of the bioavailability of faminophylline in a conventional base and a continuous-release base. J. Clin. Pharmacol. 1973; 13: 383–387
   PubMed Web of Science ®Google Scholar
• Bredenberg S., Duberg M., Lennernas B., Lennernas H., Pettersson A., Westerberg M. In vitro and in vivo evaluation of a new sublingual tablet system for rapid oromucosal absorption using fentanyl citrate as the active substance. Eur. J. Pharm. Sci. 2003; 20: 327–334
   PubMed Web of Science ®Google Scholar
• Caldwell J. R., Rapoport R. J., Davis J. C., Offenberg H. L., Marker H. W., Roth S. H., et al. Efficacy and safety of a once-daily morphine formulation in chronic, moderate-to-severe osteoarthritis pain: Results from a randomized, placebo-controlled, double-blind trial and an open-label extension trial. J. Pain Symptom Manage. 2002; 23: 278–291
   PubMed Web of Science ®Google Scholar
• Cephalon Inc. Actiq [Package insert]. Author, Salt Lake City, UT 2006
   Google Scholar
• Cephalon Inc. Fentora [Package insert. Author, Salt Lake City, UT 2006
   Google Scholar
• Chao J. Retrospective analysis of Kadian (morphine sulfate sustained-release capsules) in patients with chronic, nonmalignant pain. Pain Med. 2005; 6: 262–265
   PubMed Web of Science ®Google Scholar
• Clark A. J., Ahmedzai S. H., Allan L. G., Camacho F., Horbay G. L. A., Richarz U. Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain. Curr. Med. Res. Opin. 2004; 20: 1419–1428
   PubMed Web of Science ®Google Scholar
• Clements J. A., Nimmo W. S., Grant I. S. Bioavailability, pharmacokinetics, and analgesic activity of ketamine in humans. J. Pharm. Sci. 1982; 71: 539–542
   PubMed Web of Science ®Google Scholar
• Csoka I., Csanyi E., Zapantis G., Nagy E., Feher-Kiss A., Horvath G. In vitro and in vivo percutaneous absorption of topical dosage forms: Case studies. Int. J. Pharm. 2005; 291: 11–9
   PubMed Web of Science ®Google Scholar
• Darwish M., Kirby M., Robertson P., Jr., Tracewell W., Jiang J. G. Absolute and relative bioavailability of rentanyl buccal tablet and oral transmucosal fentanyl citrate. J. Clin. Pharmacol. 2007; 47: 343–350
   PubMed Web of Science ®Google Scholar
• findarticles.com/p/articles/mi_m0EIN/is_2003_Sept_22/ai_108001955, Depomed Acquires Exclusive Rights to Gabapentin GR. (2003). Business Wire
   Google Scholar
• findarticles.com/p/articles/mi_pwwi/is_200303/ai_mark02052163, Eichman, J. D., & Robinson, J. R. (1998). Mechanistic studies on effervescent-induced permeability enhancement. Pharm. Res. 15, 925–930
   Google Scholar
• findarticles.com/p/articles/mi_pwwi/is_200303/ai_mark02052163, Endo Pharmaceuticals. (2003). Clinical trial of new opioid product shows pain reduction in chronic low back pain
   Google Scholar
• Endo Pharmaceuticals. Opana ER [Package insert]. Author, Chadds Forth, PA 2006
   Google Scholar
• Farr S. J., Otulana B. A. Pulmonary delivery of opioids as pain therapeutics. Adv. Drug Deliv. Rev. 2006; 58: 1076–1088
   PubMed Web of Science ®Google Scholar
• Finlay I. Ketamine and its role in cancer pain. Pain Rev. 1999; 6: 303–313
   Web of Science ®Google Scholar
• Fukshansky M., Are M., Burton A. W. The role of opioids in cancer pain management. Pain Pract. 2005; 5: 43–54
   PubMedGoogle Scholar
• Fulda S., Wetter T. C. Emerging drugs for restless legs syndrome. 2005; 10(3)537–552
   PubMedGoogle Scholar
• Gallagher R. M. Primary care and pain medicine: A community solution to the public health problem of chronic pain. Med. Clin. North Am. 1999; 83: 555–583
   PubMed Web of Science ®Google Scholar
• Gallop M. A., Cundy K. C., Zhou C. X., Yao F., Xiang J.-N. Prodrugs of GABA analogs, compositions and uses thereof. U.S. Patent 6818787. 2004
   Google Scholar
• Garcia-Borreguero D., Larrosa O., de la Llave Y. Treatment of restless legs syndrome with gabapentin. Neurology 2002; 59: 1573–1579
   PubMed Web of Science ®Google Scholar
• Gourlay G. K. Sustained relief of chronic pain: Pharmacokinetics of SR morphine. Clin. Pharmacokinet. 1998; 35: 173–190
   PubMed Web of Science ®Google Scholar
• Gusler G., Berner B., Chau M., Padua M. Optimal polymer mixtures for gastric retentive tablets. U.S. Patent 6723340. 2004
   Google Scholar
• Hagen N. A., Thirlwell M., Eisenhoffer J., Quigley P., Harsanyi Z., Darke A. Efficacy, safety, and steady-state pharmacokinetics of once-daily controlled-release morphine (MS Contin XL(R)) in cancer pain. J. Pain Symptom Manage. 2005; 29: 80–90
   PubMed Web of Science ®Google Scholar
• Higgins M. J., Asbury A. J., Brodie M. J. Inhaled nebulised fentanyl for postoperative analgesia. Anaesthesia 1991; 46: 973–976
   PubMed Web of Science ®Google Scholar
• Hocking G., Cousins M. J. Ketamine in chronic pain management: An evidence-based review. Anesth. Analg. 2003; 97: 1730–1739
   PubMed Web of Science ®Google Scholar
• Hung O. R., Sellers E. M., Kaplan H. L., Romach M. K. Phase Ib clinical trial of aerosolized liposome encapsulated fentanyl (AeroLEFTM). Clin. Pharmacol. Ther. 2004; 75: P4
   Web of Science ®Google Scholar
• Hung O. R., Whynot S. C., Varvel J. R., Shafer S. L. Pharmacokinetics of inhaled liposome-encapsulated fentanyl. Anesthesiology 1995; 83: 277–284
   PubMed Web of Science ®Google Scholar
• Janssen L. P. Duragesic [Package insert]. Author, Titusville, NJ 2003
   Google Scholar
• Jeal W., Benfield P. Transdermal fentanyl. A review of its pharmacological properties and therapeutic efficacy in pain control. Drugs 1997; 53: 109–138
   PubMed Web of Science ®Google Scholar
• Joint Commission on Accreditation of Healthcare Organizations. Pain assessment and management: An organizational approach. Author, Oakbrook Terrace, IL 2000
   Google Scholar
• Kaufman M. Painkiller Palladone pulled over alcohol risk. Washington Post July 14, 2005; A14, sect.
   Google Scholar
• Kerr R. O., Tester W. J. A. A patient preference study comparing two extended-release morphine sulfate formulations (once-daily Kadian versus twice-daily MS Contin) for cancer pain. Clin. Drug Invest. 2000; 19: 25–32
   Web of Science ®Google Scholar
• Labroo R. B., Paine M. F., Thummel K. E., Kharasch E. D. Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4: Implications for interindividual variability in disposition, efficacy, and drug interactions. Drug Metab. Dispos. 1997; 25: 1072–1080
   PubMed Web of Science ®Google Scholar
• Leslie S. The Contin delivery system: Dosing considerations. J. Allergy Clin. Immunol. 1986; 78: 768–773
   PubMed Web of Science ®Google Scholar
• Leslie S. T. Slow release pharmaceutical compositions. U.S. Patent 3965256. 1976
   Google Scholar
• Ligand Pharmaceuticals. Avinza [Package insert]. Author, San Diego, CA 2003
   Google Scholar
• Mather L. E., Woodhouse A., Ward M. E., Farr S. J., Rubsamen R. A., Eltherington L. G. Pulmonary administration of aerosolised fentanyl: Pharmacokinetic analysis of systemic delivery. Br. J. Clin. Pharmacol. 1998; 46: 37–43
   PubMed Web of Science ®Google Scholar
• Mystakidou K., Katsouda E., Parpa E., Vlahos L., Tsiatas M. Oral transmucosal fentanyl citrate: Overview of pharmacological and clinical characteristics. Drug Deliv. 2006; 13: 269–276
   PubMed Web of Science ®Google Scholar
• Nakamura K., Nara E., Akiyama Y. Development of an oral SR drug delivery system utilizing pH-dependent swelling of carboxyvinyl polymer. J. Control. Release 2006; 111: 309–315
   PubMed Web of Science ®Google Scholar
• phx.corporate-ir.net/phoenix.zhtml?c= 123046&p=irol-newsArticle&ID=604962&highlight=, Newbould, B. (2004). Endo licenses the rights to develop and market proprietary Sublingual Fentanyl product from Orexo. Investors - News Release
   Google Scholar
• Newman S. P. Optimizing delivery of drugs to the lungs. Clin. Asthma Rev. 1998; 2: 123–128
   Google Scholar
• Newman S. P. Drug delivery to the lungs from dry powder inhalers. Curr. Opin. Pulm. Med. 2003; 9(Suppl. 1)S17–S20
   PubMed Web of Science ®Google Scholar
• Oshlack B. O., Chasin M. C., Huang H.-P. Extruded orally administrable opioid formulations. U.S. Patent 6261599. 1999
   Google Scholar
• Parke-Davis. Neurontin [Package insert]. Author, Morris Plains, NJ 2002
   Google Scholar
• Pather I. S., Siebert J. M., Hontz J., Kkhankari R. K., Gupte S. V., Kumbale R. Enhanced buccal delivery of fentanyl using the Ora Vescent drug delivery system. Drug Delivery Technology 2001; 1: 54–57
   Google Scholar
• Pitcairn G. R., Lankinen T., Seppälä O.-P., Newman S. P. Pulmonary drug delivery from the Taifun dry powder inhaler is relatively independent of the patient's inspiratory effort. J. Aerosol Med. 2000; 13: 97–104
   PubMedGoogle Scholar
• Portenoy R. K., Sciberras A., Eliot L., Loewen G., Butler J., Devane J. Steady-state pharmacokinetic comparison of a new, extended-release, once-daily morphine formulation, Avinza, and a twice-daily controlled-release morphine formulation in patients with chronic moderate-to-severe pain. J. Pain Symptom Manage. 2002; 23: 292–300
   PubMed Web of Science ®Google Scholar
• Prommer E. Oxymorphone: A review. Support. Care Cancer 2006; 14: 109–115
   PubMed Web of Science ®Google Scholar
• Purdue Pharma L. P. MS Contin [Package insert]. Author, Stamford, CT 2004a
   Google Scholar
• Purdue Pharma L. P. OxyContin [Package insert]. Author, Stamford, CT 2004b
   Google Scholar
• Purdue Pharma L. P. Palladone [Package insert. Author, Stamford, CT 2004c
   Google Scholar
• Reder R. F. Opioid formulations: Tailoring to the needs in chronic pain. Eur. J. Pain 2001; 5: 109–111
   PubMed Web of Science ®Google Scholar
• Rose M. A. Gabapentin: Pharmacology and its use in pain management. Anaesthesia 2002; 57: 451–462
   PubMed Web of Science ®Google Scholar
• Schmidt R. L., Sandler A. N., Katz J. Use and efficacy of low-dose ketamine in the management of acute postoperative pain: A review of current techniques and outcomes. Pain 1999; 82: 111–125
   PubMed Web of Science ®Google Scholar
• Slatkin N., Frailey A., Ma T., Ahdieh H. Oxymorphone extended release offers long-term safety, effectiveness, and dose stabilization in cancer pain: Results of a one-year interim report (Abstract). Journal of Pain 2003; 4(Suppl 1)84
   Google Scholar
• Streisand J. B., Busch M. A., Talmage D., Smith B. G., Gay M., Pace N. L. Dose proportionality and pharmacokinetics of oral transmucosal fentanyl citrate. Anesthesiology 1998; 88: 305–309
   PubMed Web of Science ®Google Scholar
• Tremont-Lukats I. W., Megeff C., Backonja M. M. Anticonvulsants for neuropathic pain syndromes. Drugs 2000; 60: 1029–1052
   PubMed Web of Science ®Google Scholar
• Turk D. C., Okifuji A. Pain terms and taxonomies of pain. Bonica's Management of Pain, J. D. Loeser, S. H. Butler, C. R. Chapman, C. R. Lippincott Williams & Wilkins, Hagerstown, MD 2000; 17–25
   Google Scholar
• Watson C. P. N., Moulin D., Watt-Watson J., Gordon A., Eisenhoffer J. Controlled-release oxycodone relieves neuropathic pain: A randomized controlled trial in painful diabetic neuropathy. Pain 2003; 105: 71–78
   PubMed Web of Science ®Google Scholar
• Westerberg M., Nyström C. Physicochemical aspects of drug release. XII. The effect of some carrier particle properties and lubricant admixture on drug dissolution from tableted ordered mixtures. Int. J. Pharm. 1991; 69: 129–141
   Web of Science ®Google Scholar
• Worsley M. H., MacLeod A. D., Brodie M. J., Asbury A. J., Clark C. Inhaled fentanyl as a method of analgesia. Anaesthesia 1990; 45: 449–451
   PubMed Web of Science ®Google Scholar
• Xanodyne Pharmaceuticals Inc. Oramorph SR [Package insert]. Author, Newport, KY 2006
   Google Scholar
• Zeppetella G. Nebulized and intranasal fentanyl in the management of cancer-related breakthrough pain. Palliat. Med. 2000; 14: 57–58
   PubMed Web of Science ®Google Scholar
• Zhang H., Zhang J., Streisand J. B. Oral mucosal drug delivery: Clinical pharmacokinetics and therapeutic applications. Clin. Pharmacokinet. 2002; 41: 661–860
   PubMed Web of Science ®Google Scholar